STAT

MARCH 3, 2025

Also, lots of updates on vaccines, and Ginkgo starts subleasing its lab space.  Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we bid adieu to NIH luminary Francis Collins.   Read the rest…

Vaccines 149

Vaccines Drug Pricing Drug Development 149

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Innovative new vaccines are being created more rapidly than ever before.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

pharmaphorum

DECEMBER 6, 2022

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent despite centring on their mRNA-based vaccines for COVID-19. It also waived its rights to bring the lawsuit when it pledged not to sure other COVID-19 vaccine producers during the pandemic, according to Reuters.

Vaccines 97

Vaccines Immunization Immunity Drug Development 97

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up.

Vaccines 65

Vaccines Immunization Immunity Drug Development 65

Pharmaceutical Business Review

AUGUST 28, 2023

These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. The study will compare the relative efficacy of next-generation vaccines against approved vaccines to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection.

Vaccines 52

Vaccines Clinical Pharmacology Immunization Immunity 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Immunity Medical Schools 59

Pharmafile

MARCH 15, 2023

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine.

Vaccines 40

Vaccines Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Immunity Hospitals 40

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Immunity Hospitals 40

STAT

OCTOBER 29, 2024

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta.

Vaccines 362

Vaccines Immunization Immunity Drug Development 362

STAT

MAY 7, 2024

Drug development is essentially a long, expensive bet: 90% of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drug development.

Drug Development 309

Drug Development Vaccines 309

STAT

FEBRUARY 14, 2023

A Marburg fever outbreak in Equatorial Guinea is galvanizing efforts to test drugs and vaccines for a virus that currently has none. But every day counts, warned experts who gathered virtually on Tuesday to try to chart a course for the work.

Vaccines 315

Vaccines Drug Development 315

STAT

MARCH 22, 2024

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday. Continue to STAT+ to read the full story…

Drug Development 351

Drug Development Vaccines 351

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunization Immunity Drug Development 115

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development 133

Drug Development Immunization Immunity Vaccines 133

STAT

SEPTEMBER 12, 2024

Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate.

Drug Development 329

Drug Development Vaccines 329

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Immunity 64

pharmaphorum

OCTOBER 30, 2020

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 That is the basis for filing for emergency use authorisation (EUA) of the vaccine in the US, according to criteria set out by the FDA. billion in deposits for the shot.

Vaccines 100

Vaccines Immunization Immunity Drug Development 100

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

STAT

MAY 22, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. About a month ago, when I first started writing this newsletter, I shared the devastating news that the famed rat hole here in Chicago  was being removed.

Drug Pricing 283

Drug Pricing Drug Development Vaccines 283

STAT

JUNE 5, 2024

We’ve got a dramatic vote on psychedelic therapy, record drug shortages, bad (maybe?) Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Jason Mast here filling in for Elaine. news for Biomarin, and a new kind of PrEP.

Drug Pricing 273

Drug Pricing Drug Development Vaccines 273

STAT

JUNE 3, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning! It’s an ASCO-full newsletter today (and be sure to peruse the More Reads for more reads) but there’s so much more this week.

Drug Pricing 261

Drug Pricing Drug Development Vaccines 261

STAT

MAY 17, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Asking again! Could you tell us what you think of The Readout? Fill out this  survey ! Read the rest…

Drug Pricing 255

Drug Pricing Drug Development Vaccines 255

STAT

APRIL 12, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with what is my final edition of The Readout on my last day at STAT.

Drug Pricing 278

Drug Pricing Drug Development Vaccines 278

STAT

APRIL 11, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at a biotech deal with a lengthy backstory, the tyranny of gas prices, and the latest shakeup at BIO. Read the rest…

Drug Pricing 276

Drug Pricing Drug Development Vaccines 276

Express Pharma

JANUARY 23, 2025

For example, the orphan drug designation (ODD) is granted to drugs intended to treat a rare condition providing tax credits for qualified clinical trials, exemptions from user fees, and a potential of seven years market exclusivity following approval. Each designation offers specific benefits to the drugmakers.

Vaccines 104

Vaccines Drug Development 104

STAT

DECEMBER 7, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with another multibillion-dollar deal, a word on the future of Sanofi, and a setback in one of medicine’s longest-running quests. Read the rest…

Drug Pricing 267

Drug Pricing Drug Development Vaccines 267

STAT

FEBRUARY 29, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete. Read the rest…

Drug Pricing 265

Drug Pricing Drug Development Vaccines 265

STAT

OCTOBER 4, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the precarious case of gene therapy in Europe, a long-awaited coup for Novavax, and the unwinding of Amgen’s success story. Read the rest…

Drug Development 265

Drug Development Vaccines 265

STAT

FEBRUARY 26, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology. Read the rest…

Drug Pricing 260

Drug Pricing Drug Development Vaccines 260

STAT

DECEMBER 22, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter  here.

HIPAA 256

HIPAA Drug Pricing Drug Development Hospitals 256

STAT

OCTOBER 10, 2023

The state’s biotech scene   exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. And although many companies are making layoffs, others are expanding.

Vaccines 335

Vaccines Generic Medicine Drug Development Packaging 335

STAT

MARCH 31, 2025

There were also some dissenters: those who argued one person is simply not important enough to raise concerns this big.

Vaccines 361

Vaccines Drug Development 361

STAT

OCTOBER 6, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we discuss why an advisory committee was not thrilled with Amgen’s data for Lumakras, and Neurocrine Biosciences has a potential blockbuster up its sleeve.

Drug Pricing 235

Drug Pricing Drug Development Vaccines 235

STAT

NOVEMBER 21, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at an ambitious genomics startup, some cautious optimism on Wall Street, and a rough day for an American in Germany. Read the rest…

Drug Pricing 232

Drug Pricing Drug Development Vaccines 232

STAT

FEBRUARY 1, 2024

Novavax is on thin ice Novavax, the company whose corporate missteps repeatedly sidelined an effective Covid-19 vaccine, is relying on demand for booster doses to remain solvent. And the latest update isn’t exactly encouraging.

Drug Pricing 315

Drug Pricing Vaccines Communication Drug Development 315

STAT

SEPTEMBER 23, 2024

Look at Covid, how many vaccines do we have?” “We should not be passive about it. We’re not passive about any other condition,” she told STAT. “Look at HIV, how many antiretrovirals do we have? ” Continue to STAT+ to read the full story…

Vaccines 361

Vaccines Drug Development 361